Status:
COMPLETED
A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure
Lead Sponsor:
Pfizer
Conditions:
Diastolic Heart Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The aim of this study was to determine whether long-term (≥ 6 months at the target dose) blockade of ETA receptors using sitaxsentan showed functional benefit in subjects with chronic Heart Failure an...
Eligibility Criteria
Inclusion
- 18 or older with chronic heart failure and evidence of diastolic dysfunction on echocardiogram, heart imaging, and a minimum exercise tolerance average time of 120 seconds on two treadmill tests within 2 weeks of enrollment
Exclusion
- unstable cardiovascular disease within 4 weeks of screening, history of heart attack, cardiac by-pass surgery or percutaneous intervention, stent placement, within 3 months of screening or amyloidosis, hypertrophic obstructive or restrictive cardiomyopathy, or constrictive pericarditis
Key Trial Info
Start Date :
March 27 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00303498
Start Date
March 27 2006
End Date
May 1 2008
Last Update
January 4 2023
Active Locations (52)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
2
Mobile Heart Specialists, PC
Mobile, Alabama, United States, 36608
3
Preventative and Research Cardiloogy Providence Hospital
Mobile, Alabama, United States, 36608
4
Central Arkansas Veterans HCS
Little Rock, Alaska, United States, 72205